Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.74 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.57 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.57 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.57 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.57 |
| ▸ | BACE1 | P56817 | 1/20 | 0.57 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.56 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | VNN1 | O95497 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | STAMBP | O95630 | 1/20 | 0.52 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27822779 | 0.87 | L3MBTL1 (0.81) | L3MBTL1CACNA1BAPBA1SMN1; SMN2NPC1 | |
| SCHEMBL13210574 | 0.87 | PRKAA2 (0.61) | L3MBTL1SMN1; SMN2LMNAVNN1MEN1 | |
| SCHEMBL28443041 | 0.86 | L3MBTL1 (0.74) | L3MBTL1CACNA1BAPBA1SMN1; SMN2NPC1 | |
| SCHEMBL4067449 | 0.85 | L3MBTL1 (1.00) | L3MBTL1CACNA1BAPBA1SMN1; SMN2NPC1 | |
| SCHEMBL3162987 | 0.85 | L3MBTL1 (0.69) | L3MBTL1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL28049871 | 0.84 | L3MBTL1 (0.72) | L3MBTL1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL4008158 | 0.84 | L3MBTL1 (0.54) | L3MBTL1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL31023556 | 0.83 | L3MBTL1 (0.84) | L3MBTL1KCNQ3KCNQ2CACNA1BAPBA1 | |
| SCHEMBL12516720 | 0.83 | L3MBTL1 (0.56) | L3MBTL1SMN1; SMN2LMNASTAMBPCOPS5 | |
| SCHEMBL13450238 | 0.83 | L3MBTL1 (0.58) | L3MBTL1SMN1; SMN2LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20070129367-A1 | Pyridine derivatives as cb2 receptor modulators | GLAXO GROUP LIMITED (GB) | 2007-06-07 | — | — | US | disclosed |
| US-20070129367-A1 | Pyridine derivatives as cb2 receptor modulators | GLAXO GROUP LIMITED (GB) | 2007-06-07 | — | — | US | disclosed |
| US-20070129367-A1 | Pyridine derivatives as cb2 receptor modulators | GLAXO GROUP LIMITED (GB) | 2007-06-07 | — | — | US | disclosed |
| EP-1732561-A1 | COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2006-12-20 | — | — | EP | disclosed |
| EP-1562907-B1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005074939-A1 | COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2005-08-18 | — | — | WO | disclosed |
| EP-1562907-A1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004029027-A1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129367-A1 | Pyridine derivatives as cb2 receptor modulators | CNR2, CNR1, TRPV1 | L3MBTL1 4699/4885KCNQ3 683/4885KCNQ2 590/4885 |
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | CNR2, CNR1, PDE4A | L3MBTL1 4731/4885KCNQ3 2055/4885KCNQ2 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.